Last A$0.13 AUD
Change Today 0.00 / 0.00%
Volume 10.0K
NRT On Other Exchanges
Symbol
Exchange
NASDAQ CM
OTC US
Frankfurt
Stuttgart
As of 8:29 PM 07/22/14 All times are local (Market data is delayed by at least 15 minutes).

novogen ltd (NRT) Snapshot

Open
A$0.13
Previous Close
A$0.13
Day High
A$0.13
Day Low
A$0.13
52 Week High
11/14/13 - A$0.40
52 Week Low
07/21/14 - A$0.12
Market Cap
21.9M
Average Volume 10 Days
228.7K
EPS TTM
A$-0.02
Shares Outstanding
168.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NOVOGEN LTD (NRT)

Related News

No related news articles were found.

novogen ltd (NRT) Related Businessweek News

No Related Businessweek News Found

novogen ltd (NRT) Details

Novogen Limited operates as a pharmaceutical drug development company worldwide. It focuses on the development of a family of anti-cancer drugs based on super-benzopyran and stealth drug technologies. The company’s lead drug candidate is CS-6, a mitochondrial electron transfer inhibitor for the treatment of temozolomide-resistant glioblastoma multiforme and late-stage chemo-refractory ovarian cancer. Novogen Limited was founded in 1994 and is based in Hornsby, Australia.

Founded in 1994

novogen ltd (NRT) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: A$118.1K
Vice-President of Drug Discovery, Manufacture...
Total Annual Compensation: A$103.5K
Chief Scientific Officer
Total Annual Compensation: A$31.3K
Compensation as of Fiscal Year 2013.

novogen ltd (NRT) Key Developments

Novogen and CanTx Announce Potency of Intra-Peritoneal Trx-1 Confirmed against Chemo-Resistant Ovarian Cancer Stem Cells

Novogen Limited and CanTx Inc., its joint venture with Yale University announced the success of proof-of-concept pre-clinical studies confirming the potency of experimental drug, Trx-1, in the treatment of primary ovarian cancer when delivered into the peritoneal cavity. Based on the potency seen in animal models to date, and the potential to prevent recurrence, Novogen and CanTx believe that Intra-Peritoneal Trx-1 could be utilized as a first-line therapy for ovarian cancer. Trx-1 is being developed for the treatment of ovarian cancer, particularly for its ability to kill chemo-resistant ovarian cancer stem cells. Novogen and CanTx plan to file an Investigational New Drug application (IND) with the FDA in early 2015 and to start a Phase 1 study by mid-2015. The data presented on June 17, 2014 shows that Trx-1 can significantly retard the growth of highly chemo-resistant, human ovarian cancer stem cells in an animal model considered to be highly representative of the human situation. The animal model developed at Yale involves injecting human CD44+/MyD88+ (cancer stem) cells into the peritoneal cavity of mice, where they quickly establish highly aggressive multiple tumors comprising both CD44+/MyD88+ cells and recurrent CD44-/MyD88- cells, all highly chemo-resistant. This animal model is representative of the human situation where ovarian cancer generally is confined to the abdomen and the cells are free to spread, leading to multiple tumors often involving dozens or even hundreds of individual tumors. Faced with the challenge of treating such scattered tumor load, the injection of anti-cancer drugs directly into peritoneal cavity is an approach clinicians have long considered.

Novogen Identifies Highly Active Drug Candidates Against Prostate Cancer

Novogen Limited announced that with its super-benzopyran (SBP) drug program, having identified a number of SBP compounds with potent anti-cancer activity against human prostate cancer cells in vitro. As a result, Novogen has extended its preclinical SBP program to include prostate cancer as well as ovarian and brain cancers. Prostate cancer cells are highly resistant to chemotherapy and the few drugs approved for late-stage, hormone-resistant prostate cancer offer only modest improvements in survival. There is thus an urgent need to develop drugs specifically against prostate cancer that will prolong life to a meaningful degree for these advanced patients. In a study conducted by Australian oncologist, Paul de Souza, M.D., Foundation Professor in Medical Oncology at the University of Western Sydney's (UWS) and who is also affiliated with the Ingham Institute, a number of SBP compounds were tested in vitro against five different prostate cancer cell lines that most closely mimic common clinical situations. There is a significant need for more effective treatments for prostate cancer. It's exciting at long last to be working with new compounds with such impressive activity against a panel of clinically-relevant prostate cancer cell lines. The studies in the laboratory of Professor de Souza are funded by Novogen and are part of an international research program initiated and coordinated by Novogen and involving some of the world's most prestigious universities and hospitals. An ongoing structural-activity-relationship drug discovery program has produced a sub-family of SBP compounds with high potency against prostate cancer cells. A lead candidate compound has been identified and now will enter its lead optimization phase. Professor de Souza will be the Lead Investigator in this program, with the aim of testing the investigational drug as a monotherapy in Australia in 2015 in men with advanced prostate cancer who have failed standard of care. At the same time, Novogen will file an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) seeking permission to conduct a U.S. clinical trial, also in 2015. Novogen's proprietary SBP drug technology platform targets an oncogene that appears to be common to all forms of cancer. The oncogene produces a mutant form of an enzyme that regulates fundamental biochemical processes within all cells. When inhibited, the cell quickly dies. This mechanism of action offers the potential for SBP drugs to avoid the common problems associated with targeted therapies of the cancer cell being able to develop alternative signaling pathways or multi-drug resistance mechanisms. Other studies funded by Novogen at prestigious US universities have already have identified two SBP structures with particular activity against ovarian cancer and glioblastoma cells respectively. The prostate cancer cells used in this study respond poorly both in the laboratory and in the clinic to standard chemotherapy drugs, so ability to kill them at such low drug concentrations suggests that has broken through an important barrier.

Novogen Limited and Genea Biocells Announce Partnership to Investigate Promising New Approach to Neurodegenerative Diseases

Novogen Limited announced a collaboration with Genea Biocells, to accelerate testing of their super-benzopyran (SBP) drugs for degenerative diseases of the nervous system and muscles. Preliminary research conducted by both companies found that super-benzopyrans appear to be effective at promoting the 'normalization' of stem cells associated with some forms of neurodegeneration and muscular dystrophy, genetic disorders which result in progressive deterioration of brain function or muscle strength and function. Novogen will partner with Genea Biocells to test the molecules in laboratory models across a range of degenerative diseases including infantile neuraxonal dystrophy, fascioscapularhumeral dystrophy, amyotrophic lateral sclerosis (motor neurone disease), Sanfillipo syndrome and Alzheimer's Disease. The collaboration is on the basis of pooling respective resources, with each company retaining its own intellectual property rights and commercial opportunities.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NRT:AU A$0.13 AUD 0.00

NRT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NRT.
View Industry Companies
 

Industry Analysis

NRT

Industry Average

Valuation NRT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 40.2x
Price/Book 5.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 28.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVOGEN LTD, please visit www.novogen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.